Kestra Medical Technologies (KMTS) investor relations material

Executive summary

• Achieved Q1 FY26 revenue of $19.4 million, up 52% year-over-year, driven by higher market share, new account activations, and improved collection efforts from an expanded revenue cycle management team.

• Prescription volume for the Assure system reached 4,205, up 51% year-over-year, reflecting expanded reach to patients at risk of cardiac arrest.

• Focused on expanding sales and commercial operations, improving revenue cycle management, scaling device fleet, and building clinical evidence for the Assure system.

• Achieved a major clinical milestone by concluding enrollment in the FDA post-approval study, with results to be presented at a major cardiology conference.

• Net loss attributable to common shareholders was $25.8 million, a 16% increase from the prior year, primarily due to higher operating expenses as the company scaled commercial operations and transitioned to a public company.

Financial highlights

• Revenue grew 52% year-over-year to $19.4 million in Q1, driven by increased prescriptions and market share gains.

• Gross profit was $8.9 million, up 111% year-over-year, with gross margin expanding to 45.7% from 32.9% in the prior year period.

• GAAP operating expenses were $37.7 million, including $2.9 million in non-recurring public company costs; adjusted operating expenses were $30.3 million.

• GAAP net loss was $25.8 million, and adjusted EBITDA loss was $19.4 million, both higher than the prior year due to growth investments.

• Cash and cash equivalents totaled $201.5 million as of July 31, 2025, following the IPO in March 2025, which raised $215.8 million in net proceeds.

Outlook and guidance

• Fiscal 2026 revenue guidance raised to $88 million, a 47% increase over fiscal 2025 and up from prior guidance of $85 million.

• Expect continued gross margin expansion, targeting 70%+ margins over the next few years.

• Revenue per fit expected to benefit from higher in-network patient mix and improved revenue cycle management.

• Management expects continued revenue growth as patient adoption increases and operational efficiencies are realized.

• Steady, not back-end loaded, revenue growth anticipated throughout the year as commercial team expands.